{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T19:19:17Z","timestamp":1791314357580,"version":"4.3.1"},"reference-count":48,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T00:00:00Z","timestamp":1417392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T00:00:00Z","timestamp":1417392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2016,10,7]],"date-time":"2016-10-07T00:00:00Z","timestamp":1475798400000},"content-version":"vor","delay-in-days":676,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009836","name":"Huntington Society of Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009836","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013669","name":"Ionis Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013669","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["MOP-84438"],"award-info":[{"award-number":["MOP-84438"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1038\/mt.2014.153","type":"journal-article","created":{"date-parts":[[2014,8,7]],"date-time":"2014-08-07T11:28:01Z","timestamp":1407410881000},"page":"2093-2106","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":143,"title":["In Vivo Evaluation of Candidate Allele-specific Mutant Huntingtin Gene Silencing Antisense Oligonucleotides"],"prefix":"10.1016","volume":"22","author":[{"given":"Amber L","family":"Southwell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels H","family":"Skotte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holly B","family":"Kordasiewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael E","family":"\u00d8stergaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew T","family":"Watt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey B","family":"Carroll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Crystal N","family":"Doty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika B","family":"Villanueva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenia","family":"Petoukhov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuljeet","family":"Vaid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyun","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan M","family":"Freier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric E","family":"Swayze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Punit P","family":"Seth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clarence Frank","family":"Bennett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R","family":"Hayden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1038\/mt.2014.153_bib1","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S1474-4422(10)70245-3","article-title":"Huntington's disease: from molecular pathogenesis to clinical treatment","volume":"10","author":"Ross","year":"2011","journal-title":"Lancet Neurol"},{"key":"10.1038\/mt.2014.153_bib2","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/0092-8674(93)90585-E","article-title":"A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes","volume":"72","author":"The Huntington's Disease Collaborative Research Group","year":"1993","journal-title":"Cell"},{"key":"10.1038\/mt.2014.153_bib3","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1152\/physrev.00041.2009","article-title":"Molecular mechanisms and potential therapeutical targets in Huntington's disease","volume":"90","author":"Zuccato","year":"2010","journal-title":"Physiol Rev"},{"key":"10.1038\/mt.2014.153_bib4","first-page":"1","article-title":"Treatment of Huntington disease","author":"Videnovic","year":"2013","journal-title":"Current Treatment Options in Neurology"},{"key":"10.1038\/mt.2014.153_bib5","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1093\/brain\/awt355","article-title":"HTT-lowering reverses Huntington's disease immune dysfunction caused by NF\u03baB pathway dysregulation","volume":"137","author":"Tr\u00e4ger","year":"2014","journal-title":"Brain"},{"key":"10.1038\/mt.2014.153_bib6","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0092-8674(00)80623-6","article-title":"Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease","volume":"101","author":"Yamamoto","year":"2000","journal-title":"Cell"},{"key":"10.1038\/mt.2014.153_bib7","doi-asserted-by":"crossref","first-page":"5820","DOI":"10.1073\/pnas.0501507102","article-title":"RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model","volume":"102","author":"Harper","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1038\/mt.2014.153_bib8","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.bbrc.2006.02.141","article-title":"rAAV-mediated shRNA ameliorated neuropathology in Huntington disease model mouse","volume":"343","author":"Machida","year":"2006","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1038\/mt.2014.153_bib9","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.ymthe.2005.05.006","article-title":"Intrastriatal rAAV-mediated delivery of anti-huntingtin shRNAs induces partial reversal of disease progression in R6\/1 Huntington's disease transgenic mice","volume":"12","author":"Rodriguez-Lebron","year":"2005","journal-title":"Mol Ther"},{"key":"10.1038\/mt.2014.153_bib10","doi-asserted-by":"crossref","first-page":"17204","DOI":"10.1073\/pnas.0708285104","article-title":"Therapeutic silencing of mutant huntingtin with siRNA attenuates striatal and cortical neuropathology and behavioral deficits","volume":"104","author":"DiFiglia","year":"2007","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1038\/mt.2014.153_bib11","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.neures.2005.06.021","article-title":"Clinico-pathological rescue of a model mouse of Huntington's disease by siRNA","volume":"53","author":"Wang","year":"2005","journal-title":"Neurosci Res"},{"key":"10.1038\/mt.2014.153_bib12","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/mt.2008.50","article-title":"AAV vector-mediated RNAi of mutant huntingtin expression is neuroprotective in a novel genetic rat model of Huntington's disease","volume":"16","author":"Franich","year":"2008","journal-title":"Mol Ther"},{"key":"10.1038\/mt.2014.153_bib13","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1002\/ana.21569","article-title":"Sustained effects of nonallele-specific Huntingtin silencing","volume":"65","author":"Drouet","year":"2009","journal-title":"Ann Neurol"},{"key":"10.1038\/mt.2014.153_bib14","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1038\/mt.2009.17","article-title":"Nonallele-specific silencing of mutant and wild-type huntingtin demonstrates therapeutic efficacy in Huntington's disease mice","volume":"17","author":"Boudreau","year":"2009","journal-title":"Mol Ther"},{"key":"10.1038\/mt.2014.153_bib15","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.neuron.2012.05.009","article-title":"Sustained therapeutic reversal of Huntington's disease by transient repression of Huntingtin synthesis","volume":"74","author":"Kordasiewicz","year":"2012","journal-title":"Neuron"},{"key":"10.1038\/mt.2014.153_bib16","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1038\/81593","article-title":"Inactivation of Hdh in the brain and testis results in progressive neurodegeneration and sterility in mice","volume":"26","author":"Dragatsis","year":"2000","journal-title":"Nat Genet"},{"key":"10.1038\/mt.2014.153_bib17","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1038\/mt.2011.219","article-title":"Preclinical safety of RNAi-mediated HTT suppression in the rhesus macaque as a potential therapy for Huntington's disease","volume":"19","author":"McBride","year":"2011","journal-title":"Mol Ther"},{"key":"10.1038\/mt.2014.153_bib18","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1093\/brain\/awr333","article-title":"Six-month partial suppression of Huntingtin is well tolerated in the adult rhesus striatum","volume":"135","author":"Grondin","year":"2012","journal-title":"Brain"},{"key":"10.1038\/mt.2014.153_bib19","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/1471-2164-8-126","article-title":"CAG-encoded polyglutamine length polymorphism in the human genome","volume":"8","author":"Butland","year":"2007","journal-title":"BMC Genomics"},{"key":"10.1038\/mt.2014.153_bib20","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.ajhg.2009.02.003","article-title":"CAG expansion in the Huntington disease gene is associated with a specific and targetable predisposing haplogroup","volume":"84","author":"Warby","year":"2009","journal-title":"Am J Hum Genet"},{"key":"10.1038\/mt.2014.153_bib21","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.cub.2009.03.030","article-title":"Five siRNAs targeting three SNPs may provide therapy for three-quarters of Huntington's disease patients","volume":"19","author":"Pfister","year":"2009","journal-title":"Curr Biol"},{"key":"10.1038\/mt.2014.153_bib22","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.ajhg.2012.01.005","article-title":"Common SNP-based haplotype analysis of the 4p16.3 Huntington disease gene region","volume":"90","author":"Lee","year":"2012","journal-title":"Am J Hum Genet"},{"key":"10.1038\/mt.2014.153_bib23","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1146\/annurev.pharmtox.010909.105654","article-title":"RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform","volume":"50","author":"Bennett","year":"2010","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1038\/mt.2014.153_bib24","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1038\/mt.2011.201","article-title":"Potent and selective antisense oligonucleotides targeting single-nucleotide polymorphisms in the Huntington disease gene \/ allele-specific silencing of mutant huntingtin","volume":"19","author":"Carroll","year":"2011","journal-title":"Mol Ther"},{"key":"10.1038\/mt.2014.153_bib25","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1093\/hmg\/dds397","article-title":"A fully humanized transgenic mouse model of Huntington disease","volume":"22","author":"Southwell","year":"2013","journal-title":"Hum Mol Genet"},{"key":"10.1038\/mt.2014.153_bib26","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1021\/jm801294h","article-title":"Short antisense oligonucleotides with novel 2\u2019-4\u2019 conformationaly restricted nucleoside analogues show improved potency without increased toxicity in animals","volume":"52","author":"Seth","year":"2009","journal-title":"J Med Chem"},{"key":"10.1038\/mt.2014.153_bib27","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/9304","article-title":"Crystal structure and improved antisense properties of 2\u2019-O-(2-methoxyethyl)-RNA","volume":"6","author":"Teplova","year":"1999","journal-title":"Nat Struct Biol"},{"key":"10.1038\/mt.2014.153_bib28","doi-asserted-by":"crossref","first-page":"9634","DOI":"10.1093\/nar\/gkt725","article-title":"Rational design of antisense oligonucleotides targeting single nucleotide polymorphisms for potent and allele selective suppression of mutant Huntingtin in the CNS","volume":"41","author":"Oestergaard","year":"2013","journal-title":"Nucleic Acids Res"},{"key":"10.1038\/mt.2014.153_bib29","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/306234a0","article-title":"A polymorphic DNA marker genetically linked to Huntington's disease","volume":"306","author":"Gusella","year":"1983","journal-title":"Nature"},{"key":"10.1038\/mt.2014.153_bib30","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.cell.2012.08.002","article-title":"Single-stranded RNAs use RNAi to potently and allele-selectively inhibit mutant huntingtin expression","volume":"150","author":"Yu","year":"2012","journal-title":"Cell"},{"key":"10.1038\/mt.2014.153_bib31","doi-asserted-by":"crossref","first-page":"10166","DOI":"10.1021\/bi101208k","article-title":"Allele-selective inhibition of mutant huntingtin expression with antisense oligonucleotides targeting the expanded CAG repeat","volume":"49","author":"Gagnon","year":"2010","journal-title":"Biochemistry"},{"key":"10.1038\/mt.2014.153_bib32","doi-asserted-by":"crossref","first-page":"e24308","DOI":"10.1371\/journal.pone.0024308","article-title":"Targeting several CAG expansion diseases by a single antisense oligonucleotide","volume":"6","author":"Evers","year":"2011","journal-title":"PLoS One"},{"key":"10.1038\/mt.2014.153_bib33","doi-asserted-by":"crossref","first-page":"11270","DOI":"10.1093\/nar\/gks907","article-title":"Mechanism of allele-selective inhibition of huntingtin expression by duplex RNAs that target CAG repeats: function through the RNAi pathway","volume":"40","author":"Hu","year":"2012","journal-title":"Nucleic Acids Res"},{"key":"10.1038\/mt.2014.153_bib34","doi-asserted-by":"crossref","first-page":"10426","DOI":"10.1093\/nar\/gkt825","article-title":"Self-duplexing CUG repeats selectively inhibit mutant huntingtin expression","volume":"41","author":"Fiszer","year":"2013","journal-title":"Nucleic Acids Res"},{"key":"10.1038\/mt.2014.153_bib35","doi-asserted-by":"crossref","first-page":"8788","DOI":"10.1093\/nar\/gkt594","article-title":"RNA duplexes with abasic substitutions are potent and allele-selective inhibitors of huntingtin and ataxin-3 expression","volume":"41","author":"Liu","year":"2013","journal-title":"Nucleic Acids Res"},{"key":"10.1038\/mt.2014.153_bib36","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1038\/nbt.1539","article-title":"Allele-specific silencing of mutant huntingtin and ataxin-3 genes by targeting expanded CAG repeats in mRNAs","volume":"27","author":"Hu","year":"2009","journal-title":"Nat Biotechnol"},{"key":"10.1038\/mt.2014.153_bib37","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1002\/ajmg.b.32193","article-title":"High frequency of intermediate alleles on Huntington disease-associated haplotypes in British Columbia's general population","volume":"162B","author":"Semaka","year":"2013","journal-title":"Am J Med Genet B Neuropsychiatr Genet"},{"key":"10.1038\/mt.2014.153_bib38","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.molmed.2012.09.001","article-title":"Antisense oligonucleotide therapeutics for inherited neurodegenerative diseases","volume":"18","author":"Southwell","year":"2012","journal-title":"Trends Mol Med"},{"key":"10.1038\/mt.2014.153_bib39","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1089\/oli.2007.0034","article-title":"In situ entry of oligonucleotides into brain cells can occur through a nucleic acid channel","volume":"17","author":"Shi","year":"2007","journal-title":"Oligonucleotides"},{"key":"10.1038\/mt.2014.153_bib40","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1007\/s13311-013-0194-5","article-title":"Antisense oligonucleotides: treating neurodegeneration at the level of RNA","volume":"10","author":"DeVos","year":"2013","journal-title":"Neurotherapeutics"},{"key":"10.1038\/mt.2014.153_bib41","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S1474-4422(13)70061-9","article-title":"An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study","volume":"12","author":"Miller","year":"2013","journal-title":"Lancet Neurol"},{"key":"10.1038\/mt.2014.153_bib42","doi-asserted-by":"crossref","first-page":"6182","DOI":"10.1523\/JNEUROSCI.0857-08.2008","article-title":"Full-length human mutant huntingtin with a stable polyglutamine repeat can elicit progressive and selective neuropathogenesis in BACHD mice","volume":"28","author":"Gray","year":"2008","journal-title":"J Neurosci"},{"key":"10.1038\/mt.2014.153_bib43","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0896-6273(00)80764-3","article-title":"A YAC mouse model for Huntington's disease with full-length mutant huntingtin, cytoplasmic toxicity, and selective striatal neurodegeneration","volume":"23","author":"Hodgson","year":"1999","journal-title":"Neuron"},{"key":"10.1038\/mt.2014.153_bib44","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1097\/00005072-199805000-00001","article-title":"Huntington disease","volume":"57","author":"Vonsattel","year":"1998","journal-title":"J Neuropathol Exp Neurol"},{"key":"10.1038\/mt.2014.153_bib45","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/0014-4886(84)90162-6","article-title":"Reduced Purkinje cell density in Huntington's disease","volume":"85","author":"Jeste","year":"1984","journal-title":"Exp Neurol"},{"key":"10.1038\/mt.2014.153_bib46","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1172\/JCI25424","article-title":"Antisense oligonucleotide therapy for neurodegenerative disease","volume":"116","author":"Smith","year":"2006","journal-title":"J Clin Invest"},{"key":"10.1038\/mt.2014.153_bib47","doi-asserted-by":"crossref","first-page":"7862","DOI":"10.1523\/JNEUROSCI.22-18-07862.2002","article-title":"Caspase cleavage of mutant huntingtin precedes neurodegeneration in Huntington's disease","volume":"22","author":"Wellington","year":"2002","journal-title":"J Neurosci"},{"key":"10.1038\/mt.2014.153_bib48","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0361-9230(01)00599-8","article-title":"New anti-huntingtin monoclonal antibodies: implications for huntingtin conformation and its binding proteins","volume":"56","author":"Ko","year":"2001","journal-title":"Brain Res Bull"}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152500161630257X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152500161630257X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T16:57:47Z","timestamp":1771606667000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S152500161630257X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12]]},"references-count":48,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["S152500161630257X"],"URL":"https:\/\/doi.org\/10.1038\/mt.2014.153","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2014,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In Vivo Evaluation of Candidate Allele-specific Mutant Huntingtin Gene Silencing Antisense Oligonucleotides","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1038\/mt.2014.153","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 American Society of Gene & Cell Therapy. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}